Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 6/20 | 0.49 |
| ▸ | HPGD | P15428 | 4/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2871924 | 0.90 | ALDH1A1 (0.53) | ALDH1A1KDM4ETAAR1MAPTHPGD | |
| SCHEMBL2872022 | 0.90 | ALDH1A1 (0.57) | ALDH1A1KDM4ETAAR1MAPTHPGD | |
| SCHEMBL6190042 | 0.89 | HPGD (0.47) | ALDH1A1KDM4ETAAR1MAPTHPGD | |
| SCHEMBL2869386 | 0.88 | ALDH1A1 (0.67) | ALDH1A1KDM4ETAAR1MAPTHPGD | |
| SCHEMBL2870661 | 0.88 | ALDH1A1 (0.67) | ALDH1A1KDM4ETAAR1MAPTHPGD | |
| SCHEMBL2874159 | 0.88 | ALDH1A1 (0.53) | ALDH1A1KDM4ETAAR1MAPTHPGD | |
| SCHEMBL2869401 | 0.87 | ALDH1A1 (0.60) | ALDH1A1KDM4ETAAR1MAPTHPGD | |
| SCHEMBL2871371 | 0.85 | ALDH1A1 (0.62) | ALDH1A1KDM4ETAAR1MAPTHPGD | |
| SCHEMBL2874358 | 0.84 | ALDH1A1 (0.56) | ALDH1A1KDM4ETAAR1MAPTHPGD | |
| SCHEMBL2875371 | 0.84 | ALDH1A1 (0.49) | ALDH1A1KDM4ETAAR1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7354940-B2 | 2,5-dioxoimidazolidin-4-yl acetamines and analogues as inhibitors of metalloproteinase mmp12 | ASTRAZENECA AB (SE) | 2008-04-08 | — | — | US | claimed |
| EP-1542977-B1 | 2,5-DIOXOIMIDAZOLIDIN-4-YL ACETAMIDES AND ANALOGUES AS INHIBITORS OF METALLOPROTEINASE MMP12. | ASTRAZENECA AB (SE) | 2006-12-20 | — | — | EP | claimed |
| US-20050245586-A1 | 2,5-Dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase mmp12 | ASTRAZENECA AB (SE) | 2005-11-03 | — | — | US | claimed |
| EP-1542977-A1 | 2,5-DIOXOIMIDAZOLIDIN-4-YL ACETAMIDES AND ANALOGUES AS INHIBITORS OF METALLOPROTEINASE MMP12. | AstraZeneca AB (SE) | 2005-06-22 | — | — | EP | claimed |
| WO-2004020415-A1 | 2,5-DIOXOIMIDAZOLIDIN-4-YL ACETAMIDES AND ANALOGUES AS INHIBITORS OF METALLOPROTEINASE MMP12. | ASTRAZENECA AB (SE) | 2004-03-11 | — | — | WO | claimed |
| US-7662845-B2 | 2,5-Dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase MMP12 | ASTRAZENECA AB (SE) | 2010-02-16 | — | — | US | disclosed |
| US-7354940-B2 | 2,5-dioxoimidazolidin-4-yl acetamines and analogues as inhibitors of metalloproteinase mmp12 | ASTRAZENECA AB (SE) | 2008-04-08 | — | — | US | disclosed |
| EP-1542977-B1 | 2,5-DIOXOIMIDAZOLIDIN-4-YL ACETAMIDES AND ANALOGUES AS INHIBITORS OF METALLOPROTEINASE MMP12. | ASTRAZENECA AB (SE) | 2006-12-20 | — | — | EP | disclosed |
| US-20060276524-A1 | 2,5-Dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase MMP12 | ASTRAZENECA AB, A SWEDEN CORPORATION | 2006-12-07 | — | — | US | disclosed |
| US-20050245586-A1 | 2,5-Dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase mmp12 | ASTRAZENECA AB (SE) | 2005-11-03 | — | — | US | disclosed |
| EP-1542977-A1 | 2,5-DIOXOIMIDAZOLIDIN-4-YL ACETAMIDES AND ANALOGUES AS INHIBITORS OF METALLOPROTEINASE MMP12. | AstraZeneca AB (SE) | 2005-06-22 | — | — | EP | disclosed |
| WO-2004020415-A1 | 2,5-DIOXOIMIDAZOLIDIN-4-YL ACETAMIDES AND ANALOGUES AS INHIBITORS OF METALLOPROTEINASE MMP12. | ASTRAZENECA AB (SE) | 2004-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276524-A1 | 2,5-Dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase MMP12 | MMP12, MMP13, MMP9 | ALDH1A1 540/4885KDM4E 495/4885TAAR1 3719/4885 |
| US-20050245586-A1 | 2,5-Dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase mmp12 | MMP12, PDE12, MMP13 | ALDH1A1 441/4885KDM4E 553/4885TAAR1 3540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.